U.S. Department of Health and Human Services
Supercharging a New FDA: Marty Makary on Science, Power & Patients extends HHS from drug pricing and infant formula into the larger health-agency reform cluster. The source centers on FDA commissioner Marty Makary, but also brings in NIH research priorities, CDC vaccine guidance, and administration-wide public-health trust repair.
Howard Lutnick: How America Can Hit 6% GDP Growth in 2026 adds HHS as the lead negotiating agency in Howard Lutnick’s account of Most-Favored-Nation Drug Pricing. Lutnick says HHS handled drug-company negotiations while Commerce supplied Section 232 Tariff Authority pressure around prices and reshoring.
The U.S. Department of Health and Human Services appears in Bobbie: Laura Modi. How a Baby Formula Startup Took Market Share From Two Industry Giants as part of the policy and regulatory context around Infant Formula. Laura Modi says moving to Washington, D.C. made sense because Bobbie needed to be closer to the FDA and HHS.
The episode also says Modi was invited in 2025 to meet with HHS Secretary Robert F. Kennedy Jr. alongside larger formula-company leaders. The source-scoped lesson is that a regulated baby-food company cannot treat policy engagement as optional or partisan if the product depends on federal agencies, public-health rules, and government-program access.
Connections
- Marty Makary, NIH, CDC, Root-Cause Public Health Research, and Vaccine Schedule Trust Rebuilding - health-agency reform branches added by the Makary interview.
- Food and Drug Administration, Robert F. Kennedy Jr., and WIC - agency, secretary named in the source, and public-benefits program.
- Bobbie, Laura Modi, Infant Formula Regulatory Moat, and WIC Formula Contracting - regulated startup context.
- Most-Favored-Nation Drug Pricing, Medicare, Medicaid, CMS, and Government Benefit Fraud Matching - drug-pricing and benefit-integrity branch added by All-In.